HYBIO PHARMACEUTICAL CO., LTD.
|
Indications:
- Advanced prostate cancer
- Endometriosis
- Central precocious puberty
- Uterine fibroids
- Some cases of infertility
Mechanism of Action: Leuprorelin acts as an agonist at pituitary GnRH receptors. With continuous administration, it initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, with chronic use, it suppresses these hormones, leading to decreased testosterone in males and decreased estrogen in females.
Pharmacokinetics:
- Absorption: Depends on the formulation. Long-acting forms are developed to slowly release the drug.
- Distribution: Distributed widely in the body.
- Metabolism: Minimal metabolism, with the majority of the drug remaining intact.
- Excretion: Excreted primarily through the kidneys.
Form: Leuprorelin API is usually available as a white to off-white powder. |
Send Inquiry
|